KRAS and non-small cell lung carcinoma: Finally, it became druggable with the discovery and FDA-approval (accelerated approval) of Sotorasib (AMG 510), and Adagrasib (MRTX849) for the treatment of KRAS G12C (off-state) mutated NSCLC [13, 14].